Abstract
Objective
To evaluate the efficacy, safety, and quality of life of 5 mg mifepristone per day compared with a placebo in treating uterine fibroids.
Design
Randomized, double-blind clinical study.
Location
Eusebio Hernández Gynecology and Obstetrics Teaching Hospital, Havana, Cuba.
Subjects
One hundred twenty-four subjects with symptomatic uterine fibroids.
Treatment
One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months.
Variables in evaluating safety
Changes in fibroid and uterine volumes, changes in symptom prevalence and intensity, and changes in quality of life.
Results
Three months into treatment, fibroid volume was reduced by 28.5% in the mifepristone group with an increase of 1.8% in the placebo group (P = 0.031). There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P < 0.001), and metrorrhagia (P = 0.002) at the end of treatment. Amenorrhea was 93.1% and 4.3% in the mifepristone and placebo groups, respectively (P < 0.001). Treatment side effects were significantly greater in the mifepristone group. Estradiol levels did not differ significantly between the placebo and mifepristone groups at the end of treatment. Improvement in quality of life was significantly greater in the categories of “symptoms” (P = 0.004) and “activity” (P = 0.045) in the mifepristone group.
Conclusion
The 5 mg dosage of mifepristone presented significantly superior efficacy compared to the placebo.
Disclosure
The authors report no conflicts of interest in this work.